82 related articles for article (PubMed ID: 15321751)
1. [Effects of nolatrexed on thymidylate synthase protein expression].
Li YL; Wu SG
Di Yi Jun Yi Da Xue Xue Bao; 2004 Aug; 24(8):881-4. PubMed ID: 15321751
[TBL] [Abstract][Full Text] [Related]
2. [Effects of RNA interference and nolatrexed on thymidylate synthase expression and cell proliferation of human colorectal carcinoma LOVO cells].
Tian SB; Jing CQ; Li LP
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Nov; 15(11):1187-91. PubMed ID: 23172536
[TBL] [Abstract][Full Text] [Related]
3. Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition.
Sakoff JA; Howitt IJ; Ackland SP; McCluskey A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):225-32. PubMed ID: 14648018
[TBL] [Abstract][Full Text] [Related]
4. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.
Welsh SJ; Titley J; Brunton L; Valenti M; Monaghan P; Jackman AL; Aherne GW
Clin Cancer Res; 2000 Jun; 6(6):2538-46. PubMed ID: 10873110
[TBL] [Abstract][Full Text] [Related]
5. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331.
Webley SD; Hardcastle A; Ladner RD; Jackman AL; Aherne GW
Br J Cancer; 2000 Sep; 83(6):792-9. PubMed ID: 10952785
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.
Wang W; Marsh S; Cassidy J; McLeod HL
Cancer Res; 2001 Jul; 61(14):5505-10. PubMed ID: 11454699
[TBL] [Abstract][Full Text] [Related]
7. Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase.
Nivens MC; Felder T; Galloway AH; Pena MM; Pouliot JJ; Spencer HT
Cancer Chemother Pharmacol; 2004 Feb; 53(2):107-15. PubMed ID: 14605862
[TBL] [Abstract][Full Text] [Related]
8. [Expression of thymidylate synthase gene and recurrence of colorectal carcinoma: their relation and clinical significance].
Li S; Yu B; An P; Liang Z; Yuan S
Zhonghua Wai Ke Za Zhi; 2000 Oct; 38(10):781-3. PubMed ID: 11832164
[TBL] [Abstract][Full Text] [Related]
9. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.
Giovannetti E; Backus HH; Wouters D; Ferreira CG; van Houten VM; Brakenhoff RH; Poupon MF; Azzarello A; Pinedo HM; Peters GJ
Br J Cancer; 2007 Mar; 96(5):769-75. PubMed ID: 17339891
[TBL] [Abstract][Full Text] [Related]
10. The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition.
Webley SD; Welsh SJ; Jackman AL; Aherne GW
Br J Cancer; 2001 Aug; 85(3):446-52. PubMed ID: 11487279
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.
Wang W; McLeod HL; Cassidy J; Collie-Duguid ES
Cancer Chemother Pharmacol; 2007 May; 59(6):839-45. PubMed ID: 17119966
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors.
Rafi I; Boddy AV; Calvete JA; Taylor GA; Newell DR; Bailey NP; Lind MJ; Green M; Hines J; Johnstone A; Clendeninn N; Calvert AH
J Clin Oncol; 1998 Mar; 16(3):1131-41. PubMed ID: 9508200
[TBL] [Abstract][Full Text] [Related]
13. Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy.
Brody JR; Hucl T; Gallmeier E; Winter JM; Kern SE; Murphy KM
Cancer Res; 2006 Oct; 66(19):9369-73. PubMed ID: 17018589
[TBL] [Abstract][Full Text] [Related]
14. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
Okumura K; Mekata E; Shiomi H; Naitoh H; Abe H; Endo Y; Kurumi Y; Tani T
Cancer Chemother Pharmacol; 2008 Apr; 61(4):587-94. PubMed ID: 17520254
[TBL] [Abstract][Full Text] [Related]
15. CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells.
Takagi K; Sowa Y; Cevik OM; Nakanishi R; Sakai T
Int J Oncol; 2008 May; 32(5):1105-10. PubMed ID: 18425338
[TBL] [Abstract][Full Text] [Related]
16. Nuclear expression of thymidylate synthase in colorectal cancer cell lines and clinical samples.
Bissoon-Haqqani S; Moyana T; Jonker D; Maroun JA; Birnboim HC
J Histochem Cytochem; 2006 Jan; 54(1):19-29. PubMed ID: 15956025
[TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside.
Chu E; Callender MA; Farrell MP; Schmitz JC
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S80-9. PubMed ID: 12819937
[TBL] [Abstract][Full Text] [Related]
18. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
Temmink OH; Hoogeland MF; Fukushima M; Peters GJ
Cancer Chemother Pharmacol; 2006 Jan; 57(2):171-9. PubMed ID: 16010590
[TBL] [Abstract][Full Text] [Related]
19. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.
Yawata A; Kim SR; Miyajima A; Kubo T; Ishida S; Saito Y; Nakajima Y; Katori N; Matsumoto Y; Fukuoka M; Ohno Y; Ozawa S; Sawada J
Cancer Chemother Pharmacol; 2005 Nov; 56(5):465-72. PubMed ID: 15918040
[TBL] [Abstract][Full Text] [Related]
20. High thymidylate synthase expression is typical for sporadic MSI-H colorectal carcinoma.
Okoń K; Klimkowska A; Wójcik P; Osuch C; Papla B; Stachura J
Pol J Pathol; 2006; 57(1):29-33. PubMed ID: 16739880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
